NCT07106762 2026-03-10
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb
Phase 2/3 Recruiting
Clinical Trials
8 trialsNCT07129993 2026-03-05
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo
Phase 2/3 Recruiting
NCT06225596 2026-02-17
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited
Phase 2/3 Recruiting
NCT03022825 2025-10-16
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
ImmunityBio, Inc.
Phase 2/3 Active not recruiting
NCT01438112 2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3 Terminated
NCT01475266 2017-03-29
Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
Nippon Kayaku Co., Ltd.
Phase 2/3 Terminated
NCT00389155 2015-12-07
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
Bristol-Myers Squibb
Phase 2/3 Completed
NCT01316874 2015-06-12
Bladder Cancer
Endo Pharmaceuticals
Phase 2/3 Completed